KRAS and colorectal cancer: Shitara et al. compared Pmab plus FOLFIRI with BEV plus FOLFIRI as second-line treatment in patients with KRAS exon 2 (codon 12, codon 13) wild-type colorectal cancer who had failed first-line treatment including fluoropyrimidine, oxaliplatin, and BEV [68].